Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion.
10.3349/ymj.2017.58.3.676
- Author:
Kyou Ho LEE
1
;
Eui Chun KANG
;
Hyoung Jun KOH
Author Information
1. Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea. hjkoh@yuhs.ac
- Publication Type:Case Report
- Keywords:
Macular edema;
central retinal vein;
fovea centralis;
bevacizumab;
fluorescein angiography
- MeSH:
Aged;
Bevacizumab*;
Edema;
Endothelial Growth Factors;
Female;
Fluorescein Angiography;
Fovea Centralis;
Humans;
Intravitreal Injections;
Ischemia*;
Macular Edema*;
Retinal Vein*;
Visual Acuity
- From:Yonsei Medical Journal
2017;58(3):676-678
- CountryRepublic of Korea
- Language:English
-
Abstract:
This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO). A 71-year-old female was treated with an intravitreal bevacizumab injection for macular edema following CRVO. Despite successfully decreased edema one month after injection, the postinjection best-corrected visual acuity immediately decreased from 20/40 to 20/1000 (Snellen equivalent). The FAZ area increased from 0.37 mm² to 3.11 mm² (8.4-fold increase). While intravitreal anti-vascular endothelial growth factor is effective and should be considered as a first-line treatment for macular edema secondary to CRVO, it may aggravate macular ischemia.
